Last updated: 18 June 2019 at 5:18am EST

Michael S Aberman Net Worth




The estimated Net Worth of Michael S Aberman is at least $12.8 Миллион dollars as of 21 June 2017. Michael Aberman owns over 4,500 units of Regeneron Pharmaceuticals stock worth over $10,493,350 and over the last 15 years Michael sold REGN stock worth over $2,319,749.

Michael Aberman REGN stock SEC Form 4 insiders trading

Michael has made over 18 trades of the Regeneron Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Michael exercised 4,500 units of REGN stock worth $137,835 on 21 June 2017.

The largest trade Michael's ever made was exercising 12,500 units of Regeneron Pharmaceuticals stock on 13 May 2013 worth over $300,000. On average, Michael trades about 5,050 units every 85 days since 2010. As of 21 June 2017 Michael still owns at least 9,193 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Michael Aberman stock trades at the bottom of the page.



Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis и Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.



What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.



Complete history of Michael Aberman stock trades at Regeneron Pharmaceuticals

инсайдер
Транзакция
Транзакция
Общая стоимость
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $137,835
21 Jun 2017
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $96,000
16 Dec 2015
Michael S Aberman
SVP Strategy Investor Relation
Продажа $2,319,749
23 Mar 2015
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $273,552
17 Mar 2015
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $229,725
23 Feb 2015
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $180,000
13 Feb 2015
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $72,000
22 Aug 2014
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $455,263
18 Aug 2014
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $229,725
14 Feb 2014
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $93,600
17 Jun 2013
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $300,000
13 May 2013
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $200,016
6 May 2013
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $28,800
18 Dec 2012
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $229,725
10 Dec 2012
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $200,016
29 Nov 2012
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $12,000
24 May 2012
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $300,000
30 Apr 2012
Michael S Aberman
SVP Strategy Investor Relation
Реализация опциона $300,000
2 Sep 2011


Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: